Minutes: Steering Board Meeting, 17 August 2020

The	verified that all participants attending the meeting had signed the
declaration of confider	tiality and absence of conflict of interest.
1. Update on Ast	raZeneca contract transmission
States (MS) successfu	he European Commission (EC) received confirmations that Member lly completed the opening operation of the encrypted AstraZeneca (AZ) tions were received from the following MSs:
Member States () had not sent the confirmation before the meeting.
contract due to the abs meeting, and countries promised to circulated <i>Vademecum</i>	curopean Commission Secretariat to resend both the password and the sence of representatives previously nominated to receive them. During the confirmed that they received both the password and the contract. Both follow up by sending a confirmation email as soon as possible, as per the on Contract Transmission. promised to contact colleagues in ministration to ensure that the contract reached them in good order.
Note post meeting: 27	MS confirmed that they received and were able to open the contract.
	AZ vaccine <u>doses</u> allocation would be pro rata (Eurostat population data A complete vaccination regimen for this vaccine consists of 2 doses.
and the same of th	of the Member States informed of a potential opt out from pro rata ome Member States highlighted that they will be using the option AZ vaccine to EEA countries
doses to the EEA countsuch doses could not contract foresees . MS agreed that	ent between four MS and AZ a commitment was included to allocate some tries Due to the use of the ESI that is not under the EEA, be directly apportioned from the EC contact with AZ. However, the EC at a collective effort should be made to allocate doses to the EEA countries actice, each MS will give away of its pro rata allocation for
the benefit of EEA co	The state of the s
will be di	ectly included in the allocation and distribution table.
	ronoving into the
ESI instrument None	repaying into the of the MS disagreed with the approach. The process is managed by MS
Lor morament. None	of the file disagreed with the approach. The process is managed by Mis

and coordinated by ______. ___ mentioned that a final confirmation/practical arrangements will be concluded at a next Steering Board meeting.

3. Q&A on AZ contract

The objective of the Q&A session was to give MS an opportunity to ask any remaining questions on the AZ contract. Clarifications provided at the meeting are noted below.

<u>Timeline of delivery</u>

Post Market monitoring studies

Relationship between APA and the EU Public Procurement Directive

The Public Procurement Directive 2014/24/EC does not apply in the specific case of APA and APA does not need to be implemented using provisions of the national procurement law. As it is a procurement at the EU level, it is governed by the provisions of Regulation (EU, Euratom) 2018/1046 (the Financial Regulation) and Council Regulation (EU) 2016/369 on the provision of emergency support within the Union, as amended by Council Regulation (EU) 2020/521[3] (Article 4(5)(b) in particular).

Declaration of confidentiality and of absence of conflict of interests

EC confirmed that anyone who has access to the AZ contract or any other confidential information for the purpose of analysis and decision making process would need to sign the declaration of confidentiality and of absence of conflict of interests.

Action: EC to circulate the updated declaration of confidentiality and of absence of conflict of interests. (*done post meeting*)

Minimum number of doses

MS have to buy all doses allocated pro rata or opt out from receiving all of them. The pro rata national allocation cannot be reduced or split into smaller "packages", however,

MS can buy additional doses if they wish to do so.

5 days opt-out vs National Holidays

Public holidays declared in <u>the EU register</u> will be taken into account and the period for deciding the opt-out will be extended accordingly

Cost of delivery

AZ will deliver the vaccine to ident	ified national distribution hubs.
	. Distribution within the
countries to vaccination places w	ill need to be organised by each MS taking into account
national vaccination programmes' i	eeds.
The finalisation of the	clause was done on the basis of the position discussed in
the previous Steering Committee m	eeting. The
	as explained
1' D 11 1	

earlier. Pro rata allocation

The allocation will be calculated using Eurostat population data. Table embedded below depicts percentage allocation per Member State.



doses batches

define the exact minimum size of the vaccine batch.

Member States agreed that minimum size of a batch poses a logistic challenge for which close collaboration between neighbouring MS will be needed.

3. Feedback on meeting with companies

The negotiations are ongoing with BioNTech, CureVac and Moderna. For the latter an offer might be presented shortly.